Low-level laser therapy (LLLT; ≤ 0.5 W) is guideline-recommended in the United States for shallow-tissue oral mucositis and other superficial pathologies but has generally failed in trials for deeper tissue …
Background: Cerebral endometriosis is an exceptionally rare manifestation of extrapelvic endometriosis and remains a diagnostic challenge because its clinical and imaging features may mimic more common neurological, inflammatory, vascular, or …
Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …
Doctoral student earns NIH award to investigate endometrial cancer vulnerabilities Today@Wayne
Doctoral student earns NIH award to investigate endometrial cancer vulnerabilities today.wayne.edu
This study utilized 1990-2019 data from the Global Burden of Disease (GBD) 2019 study to comprehensively evaluate global and regional temporal trends of endometriosis burden.
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Background: This study aims to investigate the impact of chronic endometritis (CE) diagnosis and treatment on pregnancy outcomes during hysteroscopic fallopian tube catheterization combined with laparoscopy in infertility patients with …
Endometriosis (EMS) causes debilitating pain and reduces quality of life. Whether pelvic floor muscle training (PFMT) provides independent, additive benefits beyond standard postoperative hormonal suppression remains unknown.
To compare the clinical effectiveness of combined oral contraceptive pills (levonorgestrel-containing COC) and dienogest in the management of endometriosis-associated chronic pelvic pain and related symptoms.